Occurrence and toxicological assessment of selected active pharmaceutical ingredients in effluents of pharmaceutical manufacturing plants and wastewater treatment plants in Kampala, Uganda

Simple item page
dc.contributor.authorKayiwa, R.
dc.contributor.authorKasedde, H.
dc.contributor.authorLubwama, M.
dc.contributor.authorKirabira, J. B.
dc.contributor.authorKayondo, Timothy
dc.date.accessioned2023-07-10T15:07:19Z
dc.date.available2023-07-10T15:07:19Z
dc.date.issued2022
dc.description.abstractThere is an increasing eco-toxicological risk associated with pharmaceuticals globally. The prevalence of six active pharmaceutical ingredients (APIs) was studied in effluents of three pharmaceutical manufacturing plants (PMPs) and two wastewater treatment plants (WWTPs) in Kampala, Uganda to ascertain the removal potentials for APIs. The APIs include atenolol, losartan, carbamazepine, sulfamethoxazole, clarithromycin, and diclofenac. The APIs were extracted using solid-phase extraction cartridges and concentrations were analyzed using a liquid chromatography-mass spectrometer system. The concentration ranges of the APIs were <limit of detection (LOD), <LOD – 4.75, <LOD – 1.37, <LOD – 1.17, and 0.28–19.55 mgL−1 for losartan, diclofenac, sulfamethoxazole, carbamazepine, and clarithromycin respectively in effluents of WWTPs, whereas in treated wastewater from PMPs concentrations were 0.00, 0.00–0.23, 5.30–7.4, 0.00–0.14, and 0.12–4.53 mgL−1 for losartan, diclofenac, sulfamethoxazole, carbamazepine, and clarithromycin respectively. The API removal efficiency of PMPs was higher than WWTPs with some APIs removed to concentrations of <LOD. The range of hazard quotients (HQs) for APIs was 0.018–0.9775000 with most of the APIs posing remarkably high environmental risks at HQs way greater than 1. Only sulfamethoxazole from the effluents of Lubigi WWTP, Bugolobi WWTP, and PMP C posed low risks with HQs of <1 at 0.018, 0.305, and 0.018 respectively. The high HQs for most APIs imply that immediate recipients are at very high toxicological risks, yet most studies have focused on the final destinations of APIs in environments where toxicological risks are often minimal due to dilution effects.en_US
dc.identifier.citationKayiwa, R., Kasedde, H., Lubwama, M., Kirabira, J. B., & Kayondo, T. (2022). Occurrence and toxicological assessment of selected active pharmaceutical ingredients in effluents of pharmaceutical manufacturing plants and wastewater treatment plants in Kampala, Uganda. Water Practice & Technology, 17(4), 852-869.https://doi.org/10.2166/wpt.2022.024en_US
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/9049
dc.language.isoenen_US
dc.publisherWater Practice & Technologyen_US
dc.subjectWastewater treatment plantsen_US
dc.subjectRisk assessmenten_US
dc.subjectActive pharmaceutical ingredientsen_US
dc.subjectPharmaceutical manufacturing plantsen_US
dc.titleOccurrence and toxicological assessment of selected active pharmaceutical ingredients in effluents of pharmaceutical manufacturing plants and wastewater treatment plants in Kampala, Ugandaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Occurrence and toxicological assessment of selected active pharmaceutical ingredients in effluents of pharmaceutical manufacturing plants and wastewater treatment plants in Kampala, Uganda.pdf
Size:
716.08 KB
Format:
Adobe Portable Document Format
Description:
Occurrence and toxicological assessment of selected active pharmaceutical ingredients in effluents of pharmaceutical manufacturing plants and wastewater treatment plants in Kampala, Uganda
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences